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Down-regulation of hepatic LDL receptor-related protein
(LRP) in chronic renal failure.
Background. Chronic renal failure (CRF) is associated
with premature atherosclerosis, impaired high-density lipopro-
tein (HDL)-mediated reverse cholesterol transport, depressed
clearance, and elevated plasma concentrations of very low-
density lipoprotein (VLDL), chylomicrons, and their athero-
genic remnants. LDL receptor-related protein (LRP) is a
member of the LDL receptor gene family that is heavily ex-
pressed in the liver, and mediates removal of at least 30 differ-
ent ligands, including VLDL remnants (IDL) and chylomicron
remnants. This study was conducted to test the hypothesis that
the well-known defect in clearance of IDL and chylomicron
remnants in CRF may be indicative of diminished hepatic LRP
abundance.
Methods. Hepatic tissue LRP mRNA abundance [reverse
transcription-polymerase chain reaction (RT-PCR)] and pro-
tein abundance (Western blot analysis) were determined in rats
8 weeks after 5/6 nephrectomy (CRF group) or sham operation
(control group).
Results. The CRF group exhibited hypertension, diminished
creatinine clearance, increased plasma triglyceride concentra-
tion, and elevated total cholesterol-to-HDL cholesterol con-
centration ratio compared to the corresponding values found in
the control group. This was associated with a significant down-
regulation of hepatic LRP mRNA expression and immunode-
tectable LRP protein.
Conclusion. CRF results in down-regulation of hepatic LRP.
This abnormality can, at least in part, account for the previously
documented elevation of plasma concentration and depressed
clearance of chylomicron remnants and IDL in CRF.
Chronic renal failure (CRF) is associated with in-
creased risk of atherosclerotic cardiovascular disease
[1, 2] and profound alterations of plasma lipid pro-
file [3–5]. CRF-associated dyslipidemia is marked by
impaired high-density lipoprotein (HDL) maturation,
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hypertriglyceridemia, elevated plasma concentration,
and defective clearance of very low-density lipopro-
tein (VLDL), chylomicrons (CM), and their highly
atherogenic remnants (IDL and CM remnants) [3–8].
Intermediate-density lipoprotein (IDL) and CM rem-
nants are the by-products of lipolysis of VLDL and CM,
respectively, by lipoprotein lipase in the circulation. CM
remnants are removed from the circulation by the liver
via hepatic LDL receptor-related protein (LRP) [9, 10].
IDL particles are either converted to LDL via further
lipolysis by hepatic triglyceride lipase or are removed
from the circulation by the liver via receptor-mediated
endocytosis. LRP is a member of the LDL receptor gene
family that is heavily expressed in the liver [11]. This high-
molecular-weight (600 kD) receptor has substantial struc-
tural similarity to LDL receptor, and recognizes a wide
array of diverse ligands, including ApoB 48- and ApoE-
enriched lipoproteins (CM remnants, IDL, HDL), hep-
atic triglyceride lipase, coagulation factors, fibrinolytic
enzymes, protease inhibitors, and protease-protease in-
hibitor complexes [12–15].
In view of the critical role of hepatic LRP in clearance
of CM remnants, IDL, and proteinase-inhibitor com-
plexes, we hypothesized that the reported increased in
plasma concentration of CM remnants, IDL [6–8], and in-
activated coagulation enzymes [16] in CRF may be indica-
tive of hepatic LRP deficiency. Accordingly, hepatic tissue
LRP gene expression and protein abundance were deter-
mined in rats 8 weeks after 5/6 nephrectomy or sham op-
eration. The results showed significant down-regulation
of hepatic LRP mRNA and protein expressions in the
CRF animals, thus confirming the original hypothesis.
METHODS
Animal models
Male Sprague-Dawley rats weighing 225 to 250 g were
purchased from Harlan Sprague Dawley, Inc. (Indianapo-
lis, IN, USA). They were housed in a climate-controlled,
light-regulated facility with 12:12-hour day-night cycles.
The animals were fed regular rat chow (Purina Mills,
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Table 1. Primers used for measurements of LRP mRNA and 18s
rRNA by RT-PCR
Product
Gene DNA sequences bp
LRP Forward 5′-GGCTGCTGATGGCTCCCGAC-3′ 619
Reverse 5′-TCTCGTCCGTGCTGGCCAGG-3′
18s Forward 5′-AGGAATTGACGGAAGGGCAC-3′ 324
rRNA Reverse 5′-GTGCAGCCCCGGACATCTAAG-3′
Brentwood, MO, USA) and water ad libitum, and were
randomly assigned to the CRF and control groups. The
animals assigned to the CRF group were subjected to
5/6 nephrectomy by surgical resection using a dorsal inci-
sion, as described previously [17]. The animals assigned to
the control group were subjected to sham operation. All
surgical procedures were carried out under general anes-
thesia (Na pentobarbital 50 mg/kg IP). Strict hemostasis
and aseptic techniques were observed. The animals were
observed for 8 weeks.
At the conclusion of the 8-week observation period,
the animals were placed in metabolic cages for a 24-hour
urine collection. They were then killed by exsanguination
via cardiac puncture between the hours of 9 and 11 a.m.
Liver was removed immediately, snap-frozen in liquid
nitrogen, and stored at −70◦C until processed. Serum
triglyceride, VLDL, HDL, and creatinine concentrations
and urinary creatinine were determined using standard
laboratory methods. The protocol employed in this study
was approved by the Institutional Committee for Care
and Use of Animals at the University of California, Irvine.
RNA isolation and RT-PCR
RNA was isolated from frozen liver using TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) and purified
by RNeasy kit (Qiagen, Valencia, CA, USA). One tenth
microgram total RNA from each sample was reverse tran-
scribed to cDNAs by using MuLV reverse transcriptase
(Applied Biosystems, Foster City, CA, USA) with a mix-
ture of 1 mmol/L dNTP and 2.5 lmol/L random primers
in a 10 lL volume for 10 minutes at 25◦C and 30 minutes
at 48◦C. The reaction was stopped by heating at 94◦C for
5 minutes.
Expression of LRP mRNA was assessed by reverse
transcription-polymerase chain reaction (RT-PCR) using
18s ribosomal RNA as internal control. The primer se-
quences used are depicted in Table 1. The primers were
designed with Primer3 program purchased from Invit-
rogen. For 18s rRNA amplification, we used alternate
18s primers (Ambion, Austin, TX, USA), which yields
a 324-bp product. In each PCR reaction, 18s ribosomal
RNA was coamplified with the target cDNA. The primers
were tested for their compatibility with the alternate
18s primer. The cDNAs were amplified using standard
PCR buffer, 0.2 mmol/L dNTP, 1 lmol/L LRP primer set,
0.5 lmol/L 18s primer/competimer mix, 2 mmol/L MgCl2,
Table 2. Creatinine clearance (Ccr), plasma concentrations of
creatinine, triglycerides, total cholesterol, and VLDL cholesterol, and
plasma total cholesterol-to-HDL cholesterol ratio in the
sham-operated control rats (CTL) and rats with chronic renal failure
(CRF)
Groupa CTL CRF P value
Ccr mL/min 2.6 ± 0.2 0.56 ± 0.09 <0.01
Creatinine mL/dL 0.4 ± 0.01 1.3 ± 0.2 <0.01
Triglycerides mg/dL 47 ± 4.5 166 ± 17 <0.01
Total cholesterol 59 ± 2.2 124 ± 11 <0.01
VLDL cholesterol mg/dL 9.3 ± 0.9 33 ± 3.4 <0.01
Total/HDL cholesterol, ratio 2.7 ± 0.3 3.7 ± 0.5 <0.05
aN = 6 in each group.
and 1.25 U of Taq DNA polymerase (Applied Biosys-
tems) in 50 lL of total volume for 30 cycles. Each cycle
consisted of 1-minute denaturation at 94◦C and 45 sec-
onds annealing at 60◦C, and 45 seconds extension at 72◦C.
PCR products were separated on a 1.2% agarose gel with
ethidium bromide by eletrophoresis. Signal intensity was
determined by laser scanning densitometry. On each oc-
casion, the LRP mRNA abundance was normalized to
the corresponding 18s ribosomal RNA.
Measurements of LRP protein
LRP receptor protein abundance in the liver tissue was
measured by Western blot analysis using a monoclonal
antihuman LRP antibody prepared in our laboratory us-
ing the IgG-11H4 hybridoma cell line purchased from
ATCC (Manassas, VA, USA).
Data analysis
Student t test was used in statistical analysis of the data,
which are given as mean ± SEM. P values less than 0.05
were considered significant.
RESULTS
General data
Creatinine clearance in the CRF group (0.56 ±
0.9 mL/min) was significantly lower than that found in the
control group (2.6 ± 0.2 mL/min, P < 0.001). In contrast,
systolic arterial pressure was significantly higher in the
CRF group (165 ± 4 mm Hg) than in the sham-operated
control rats (123 ± 2 mm Hg, P < 0.01). Body weight
obtained at the conclusion of the study was significantly
lower in the CRF group (366 ± 6 g) than in the control
group (389 ± 16 g). Compared with the control group, the
CRF animals showed a marked increase in plasma triglyc-
erides, VLDL cholesterol, and total cholesterol-to-HDL
cholesterol ratio (Table 2).
Liver LRP data
Data are shown in Figures 1 and 2. Compared with the
sham-operated control rats, the CRF group exhibited a
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Fig. 1. Representative reverse transcription-polymerase chain reac-
tion (RT-PCR) and group data depicting hepatic LDL receptor-related
protein (LRP) mRNA and 18s ribosomal RNA abundance in chronic
renal failure (CRF) and sham-operated control rats. N = 6 in each
group, ∗P < 0.05.
significant reduction of LRP mRNA abundance normal-
ized against 18s ribosomal RNA. Similarly, immunode-
tectable LRP protein abundance was significantly lower
in the liver of the CRF rats than the corresponding value
found in the sham-operated control group.
DISCUSSION
The main features of the CRF-induced dyslipidemia
include hypertriglyceridemia, elevated plasma concen-
tration, and impaired clearance of triglyceride-rich
lipoproteins (VLDL and CM) and their remnants, cou-
pled with a defective HDL maturation [3–8]. Hyper-
triglyceridemia in this model is not caused by increased
hepatic triglyceride synthesis because acyl-CoA: diglyc-
erol acyltransferase (DGAT), which is the final step
in triglyceride biosynthesis, is down-regulated in the
CRF liver [18]. Instead, it is primarily caused by down-
regulations of skeletal muscle and adipose tissue lipopro-
tein lipase [17, 19–21], which is essential for the lipolysis
of VLDL and CM, and of VLDL receptor [22, 23], which
is involved in the peripheral uptake of VLDL. This is ac-
companied by hepatic triglyceride lipase deficiency [21,
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Fig. 2. Representative Western blot and group data depicting hepatic
LDL receptor-related protein (LRP) and actin abundance in the chronic
renal failure (CRF) and sham-operated control groups. N = 6, ∗P < 0.01.
24], which plays a critical role in the removal of the
remaining triglycerides in the IDL particles and their
eventual conversion to LDL. The role of lipoprotein li-
pase, hepatic triglyceride lipase, and VLDL receptor in
metabolism of endogenous and exogenous plasma lipids
is depicted in Figure 3. The effects of lipoprotein lipase,
VLDL receptor, and hepatic triglyceride lipase deficien-
cies on metabolism of triglyceride-rich lipoproteins are
compounded by impaired maturation of HDL-3 to HDL-
2 in CRF [5]. The latter is due to down-regulation of
lecithin: cholesterol acyltransferase (LCAT), the key en-
zyme involved in HDL-mediated cholesterol uptake in
CRF [25]. HDL-2 serves as the ApoE (lipoprotein lipase
and VLDL receptor ligand) and ApoC-II (lipoprotein li-
pase cofactor) donors to the nascent VLDL and chylomi-
crons. Consequently, diminished HDL-2 level in CRF
contributes to the defective lipoprotein lipase-mediated
lipolysis of VLDL and CM and VLDL-receptor mediated
uptake of VLDL by adipocyte and myocytes. The animal
studies outlined above provided the molecular basis of
clinical studies that have demonstrated depressed plasma
LCAT activity, diminished plasma post heparin lipolytic
activity, and elevated plasma prebeta HDL (lipid-poor
HDL) in CRF patients [26–29].
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Fig. 3. Pathways of metabolism of endoge-
nous and exogenous lipids. Very low-density
lipoprotein (VLDL) and chylomicrons (CM)
are produced and secreted by the liver and in-
testine, respectively. In the circulation, VLDL
and CM undergo lipolysis by lipoprotein li-
pase (LPL) to become VLDL remnants (IDL)
and CM remnants (CMR). CMR are removed
by the liver via LRP. IDL undergo further
lipolysis by hepatic triglyceride lipase (HTL)
to become LDL, which is, in turn, removed by
either the liver via LDL receptor (LDLr) or
by extrahepatic tissues. In addition, IDL can
be directly removed from the circulation by a
receptor-mediated process. A novel pathway
has been recently identified by which VLDL
can be removed via VLDL receptor (VLDLr).
∗These proteins are down-regulated in CRF.
The CRF animals employed in the present study exhib-
ited a significant reduction of immunodetectable LRP in
the liver tissue. This was accompanied by a parallel re-
duction of LRP mRNA abundance. Thus, CRF results in
down-regulation of LRP at the level of gene transcrip-
tion. The observed hepatic LRP deficiency, shown for
the first time here, provides the molecular mechanism
of the elevated plasma concentration of the atherogenic
CM remnants in CRF [6–8].
In addition, hepatic LRP deficiency can, in part, con-
tribute to elevation of plasma IDL in CRF. As noted
earlier, CRF results in down-regulation of hepatic triglyc-
eride lipase [21, 24], which, in turn, impedes conversion
of IDL to LDL via the lipolytic pathway. This leads to
a rise in the available supplies of IDL for clearance via
the receptor-mediated endocytosis, commonly known as
the shunt pathway. LRP plays an important part in hep-
atic clearance of IDL through the shunt pathway [11,
12]. Consequently, the combined down-regulations of
the hepatic triglyceride lipase and LRP work in con-
cert to impair IDL clearance and raise plasma concen-
tration of this oxidation-prone, atherogenic lipoprotein
remnant by limiting the lipolytic and shunt pathways
of its metabolism. By promoting accumulation of highly
atherogenic CM remnants and IDL in the plasma, hepatic
LRP deficiency can contribute to the atherogenic diathe-
sis in CRF. In addition, hepatic LRP deficiency has been
shown to promote atherosclerosis in LRP knockout mice,
independent of its action on lipoprotein metabolism [30].
This phenomenon has been attributed to the accumu-
lation of other proatherogenic ligands of LRP. Thus, ac-
quired hepatic LRP deficiency can be added to many pre-
viously identified risk factors for cardiovascular disease
in CRF.
CONCLUSION
CRF results in acquired hepatic LRP deficiency, which
can contribute to the atherogenic diathesis and elevated
plasma lipoprotein remnants in chronic renal failure.
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